1.77  0.02 (1.14%)		10-04 16:00
Open: 1.78 High: 1.805 Volume: 118,965		Pre. Close: 1.75 Low: 1.75 Market Cap: 88(M)

Short term
Mid term
Targets	6-month :	2.14	1-year :	2.25
Resists	First :	1.83	Second :	1.92
Pivot price	1.78
Supports	First :	1.67	Second :	1.39
MAs	MA(5) :	1.77	MA(20) :	1.77
	MA(100) :	6.11	MA(250) :	11.13
MACD	MACD :	-0.1	Signal :	-0.2
%K %D	K(14,3) :	32.6	D(3) :	40.7
RSI	RSI(14): 37.8
52-week	High :	20.21	Low :	1.54

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ HLVX ] has closed above bottom band by 30.3%. Bollinger Bands are 98.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 49 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	1.81 - 1.81	1.81 - 1.82
Low:	1.73 - 1.74	1.74 - 1.75
Close:	1.75 - 1.77	1.77 - 1.78

HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. It is developing HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company is headquartered in Boston, Massachusetts.

Wed, 02 Oct 2024
Point72 Asset Management L.P. Makes New $6.96 Million Investment in HilleVax, Inc. (NASDAQ:HLVX) - MarketBeat

Fri, 27 Sep 2024
HC Wainwright & Co. Downgrades HilleVax (HLVX) - MSN

Thu, 01 Aug 2024
HilleVax hobbling on but cuts 40% of workers - The Pharma Letter

Thu, 01 Aug 2024
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of HilleVax, Inc. - HLVX - PR Newswire

Fri, 19 Jul 2024
HilleVax, Inc. (HLVX) Investigation: Bronstein, Gewirtz & - GlobeNewswire

Tue, 09 Jul 2024
HilleVax (HLVX) Tanks as Norovirus Vaccine Study in Infants Fails - Yahoo Finance

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	50 (M)
Shares Float	24 (M)
Held by Insiders	17.1 (%)
Held by Institutions	92.3 (%)
Shares Short	1,860 (K)
Shares Short P.Month	1,890 (K)

EPS	-3.39
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	4.28
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-31.9 %
Return on Equity (ttm)	-73.8 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-2.85
Qtrly Earnings Growth	0 %
Operating Cash Flow	-111 (M)
Levered Free Cash Flow	-82 (M)

PE Ratio	-0.53
PEG Ratio	0
Price to Book value	0.41
Price to Sales	0
Price to Cash Flow	-0.8

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.